Zhao S, Chen K, Shi X, Sun J, et al. Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemor Clin Lung Cancer 2023 Jun 15:S1525-7304(23)00135.
PMID: 37442748